Latest Shows

  • M
  • T
  • W
  • T
  • F

Breakingviews: M&A lacking Elan (3:01) 

Feb 25 - Royalty Pharma's $6.6 bln approach for the biotech is at a scrawny 4 percent premium. Richard Beales and Robert Cyran discuss why the specialist investor may still be the right owner – at the right price.

Share this video